Kintor Pharmaceutical Limited
KNTPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $3 | $3 | $0 |
| % Growth | -67.3% | 0% | – | – |
| Cost of Goods Sold | $3 | $5 | $5 | $0 |
| Gross Profit | -$2 | -$2 | -$2 | -$7 |
| % Margin | -214.8% | -94.6% | -94.6% | – |
| R&D Expenses | $5 | $39 | $39 | $1 |
| G&A Expenses | $0 | $31 | $31 | $28 |
| SG&A Expenses | $4 | $44 | $44 | $0 |
| Sales & Mktg Exp. | $0 | $13 | $13 | $7 |
| Other Operating Expenses | $0 | -$13 | -$13 | $110 |
| Operating Expenses | $10 | $70 | $70 | $111 |
| Operating Income | -$11 | -$72 | -$72 | -$1 |
| % Margin | -1,375.6% | -2,891.4% | -2,891.4% | – |
| Other Income/Exp. Net | -$0 | -$5 | -$5 | $0 |
| Pre-Tax Income | -$11 | -$78 | -$78 | -$1 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$11 | -$78 | -$78 | -$1 |
| % Margin | -1,391.5% | -3,105.8% | -3,105.8% | – |
| EPS | -0.026 | -0.027 | -0.023 | -1.98 |
| % Growth | 2.6% | -17% | 98.8% | – |
| EPS Diluted | -0.026 | -0.027 | -0.023 | -1.98 |
| Weighted Avg Shares Out | 434 | 431 | 431 | 0 |
| Weighted Avg Shares Out Dil | 434 | 431 | 431 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $2 | $1 |
| Interest Expense | $0 | $5 | $5 | $1 |
| Depreciation & Amortization | $2 | $9 | $9 | $0 |
| EBITDA | -$9 | -$64 | -$64 | -$1 |
| % Margin | -1,139.2% | -2,567.4% | -2,567.4% | – |